Key Clinical Points
• Radioactive peptide therapy with 177Lu-edotreotide proved more effective than everolimus for advanced somatostatin receptor-positive neuroendocrine tumours.
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
Conditions: Neuroendocrine Tumors
Interventions: 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution
Lead Sponsor: ITM Solucin GmbH
Planned Enrollment: 324 participants